Articles tagged with: Proteasome Inhibitors
News»
Preliminary results from an ongoing Phase 1b clinical trial suggest that carfilzomib (Kyprolis) in combination with Revlimid (lenalidomide) and low-dose dexamethasone (Decadron) is well-tolerated over extended periods of therapy in patients who have relapsed or are resistant (refractory) to previous myeloma treatment.
The findings were presented Friday at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
Carfilzomib is a new therapy being developed by Onyx Pharmaceuticals and studied for the treatment of patients with relapsed or refractory myeloma. It works similarly to Velcade (bortezomib) by preventing …
NewsFlash »
LLS Increases Financial Support For Myeloma Patients - As of Feb 1, the Leukemia & Lymphoma Society (LLS) will provide multiple myeloma patients with up to $10,000 to cover insurance-related expenses such as co-payments and insurance premiums. The new limit is an increase from the previous limit of $5,000 and is retroactive for expenses beginning July 1, 2009. For more information or to apply, please see the LLS Co-Pay Assistance Web site.
Carfilzomib Phase 3 Clinical Trial Design Is Approved – Onyx Pharmaceuticals, Inc. announced that it has reached an agreement with the Food and Drug Administration on the design and analysis of a Phase 3 clinical trial evaluating carfilzomib in relapsed myeloma. The study follows up a Phase 1B trial that examined carfilzomib in combination with Revlimid (lenalidomide) and dexamethasone (Decadron) (see related Beacon news). The Phase 3 trial is expected to begin in early to mid 2010, and the Phase 1b/2 study of this combination regimen is still recruiting participants. For more information, please see the Onyx press release.
Cancer Vaccine Produces Positive Results In Multiple Myeloma Patient – Results from a study evaluating the effects of a high dose cancer vaccine in patients with multiple myeloma, myelodysplastic syndromes, and acute myeloid leukemia showed positive immune responses in several patients. The vaccine helps the immune system kill cancer cells by building up antibodies to a protein called RHAMM, which is associated with cancer progression. In one of the three myeloma patients, the vaccine led to a decrease of the patient’s free light chains, from 10.3 mg/L to 2.26 mg/L. Side effects were limited to mild redness and infection of the skin. For more information, please see the journal Haematologica (pdf).
News»
Carfilzomib, which is a proteasome inhibitor under development as a treatment for multiple myeloma, has recently been shown to be a safe and effective treatment for myeloma patients with kidney failure, chromosomal abnormalities, or peripheral neuropathy. These results will be presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans December 5 through 8.
Additionally, ASH presenters will examine the effects of carfilzomib in patients who have previously been treated with Velcade (bortezomib) and in patients who are receiving carfilzomib in combination with Revlimid …
News»
Preliminary results from several clinical trials testing carfilzomib (Kyprolis) for the treatment of multiple myeloma will be presented at the 51st American Society of Hematology (ASH) Annual Meeting and Exposition in New Orleans December 5 through 8.
Carfilzomib, a proteasome inhibitor, is under development as a treatment for relapsed or refractory multiple myeloma. It is currently in Phase 2 of clinical testing, which means that its safety and efficacy are being studied.
The ASH presenters will examine the effects of carfilzomib in patients who have previously been treated with Velcade (bortezomib); …
News»
On Monday, Onyx Pharmaceuticals agreed to purchase Proteolix, the developer of the cancer drug carfilzomib (Kyprolis), for $276 million. Carfilzomib, which is Proteolix’s leading cancer drug, has demonstrated significant tumor-reduction activity in Phase 1 trials of patients with relapsed multiple myeloma.
Similar to Velcade (bortezomib), carfilzomib is a proteasome inhibitor that blocks the activity of these protein-destroying enzymes and induces cancer cell death. Carfilzomib is currently undergoing Phase 2 trials on patients with relapsed multiple myeloma, for which data will be reported in late 2010. Phase 3 trials combining carfilzomib with
News»
Preliminary results from an ongoing Phase 1 clinical trial indicate that carfilzomib (Kyprolis), a new proteasome inhibitor, has significant therapeutic results in patients with relapsed myeloma. The Multiple Myeloma Research Consortium (MMRC) reported the results at the Joint ECCO 15-34th ESMO Multidisciplinary Congress, which was held in Berlin from September 20 to 24.
Carfilzomib selectively induces cell death in cancer cells by blocking the activity of proteasomes, which are enzymes that break down proteins. Carfilzomib is similar to Velcade (bortezomib), the first proteasome inhibitor approved for multiple myeloma treatment. However, carfilzomib …
Resources, Treatments Under Development»
| Brand Name: | Kyprolis |
| Generic Name: | carfilzomib |
| Useful Links: | News articles, forum discussions |
| Code Name: | PR-171 |
| Company: | Onyx Pharmaceuticals |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Kyprolis, which is a second-generation proteasome inhibitor, selectively targets the enzymes that break down important proteins in cancerous cells. Multiple early-stage studies …